For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Other revenue | 0 | 1,404 | ||
| Research and development | 177 | 192 | ||
| General and administrative | 547 | 915 | ||
| Total operating expenses | 724 | 1,107 | ||
| Loss from operations | -724 | 297 | ||
| Interest income | 34 | 31 | ||
| Loss on settlement of common stock warrant liabilities | 0 | 0 | ||
| Change in fair value of warrant liabilities | 2 | -1 | ||
| Total other income (expense) | 32 | 32 | ||
| Net loss | -692 | 329 | ||
| Net loss attributable to non-controlling interests | - | -6 | ||
| Net loss attributable to avenue | -683 | 335 | ||
| Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) | -0.21 | - | ||
| Weighted average number of common shares outstanding, basic and diluted (in shares) | 3,183,558 | 3,183,558 | ||
AVENUE THERAPEUTICS, INC. (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI)